Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment

  • End date
    Jan 12, 2025
  • participants needed
  • sponsor
    Milton S. Hershey Medical Center
Updated on 4 October 2022


Investigators hypothesize that ruxolitinib 1.5% cream is an effective therapy for HS participants through inhibition of inflammatory activity.

Investigators aim to:

  • Demonstrate the clinical efficacy of ruxolitinib 1.5% cream in decreasing the clinical disease activity after 16 weeks of treatment.
  • Investigate the impact of ruxolitinib 1.5% cream on skin inflammation through translational analyses of skin biopsy samples.


The primary efficacy measure is the proportion of participants that achieve HiSCR at Week 16 with topical ruxolitinib 1.5% cream as compared to Week 0. The HiSCR is defined as an at least a 50% reduction in the total abscess and inflammatory nodule count (AN count) for all study body sites with no increase in abscess count and no increase in draining fistula count relative to Baseline. The primary efficacy analysis will be carried out on all participants who complete 16 weeks of treatment.

The research study consists of an 8 week screening with 16 weeks open-label portion.

Condition Hidradenitis Suppurativa
Treatment Ruxolitinib 1.5% cream
Clinical Study IdentifierNCT04414514
SponsorMilton S. Hershey Medical Center
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Male or female subjects age 12 years or older
Hidradenitis suppurativa, and should be Hurley Stage I or II, defined as papules, nodules, and/or abscess formation, single or multiple, with or without sinus tracts
Subjects must have a diagnosis of HS for at least 3 months (90 days) prior to Baseline
Active HS lesions must be present in at least one distinct anatomic area
Subject must have at least 3 total inflammatory lesions at the Baseline visit
Subjects who had surgery in the treatment area, should be at least 3 months status post the procedure (this applies to deroofing/marsupialization or excision, not incision & drainage)
Subject has a negative TB screening assessment (including a PPD test and/or Quantiferon-TB Gold test equivalent) OR for patients with treated latent TB or negative chest x-ray (CXR posterior-anterior [PA] and lateral view within prior 90 days) at Screening with documentation of treated latent tuberculosis (90 days of treatment)
Medications can be continued if they have been at a stable dose for the requisite duration and the dose is not increased during the study period
Biologic medication (such as TNF, IL-12/23 or IL-17 inhibitors): Up to 30% of enrolled participants will be allowed to remain on a concurrent biologic at stable dosage if treated with a stable dose and frequency for 6 months or longer
Oral antibiotic must be a stable dose and frequency for 28 days or longer
Hormone-based therapy (birth control pills or spironolactone) must be a stable dose and frequency for 4 months or longer
Oral retinoids must be on a stable dose and frequency for 90 days or longer
Other topical therapy must be discontinued 14 days prior to the Baseline visit
Child bearing potential: In addition, you must be willing to use a method of contraception during the study period and for 4 weeks after the last dose of study drug. (Note: Periodic abstinence calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable as abstinence.)

Exclusion Criteria

Infection(s) unrelated to HS requiring treatment with
intravenous (IV) anti-infectives (antibiotics, antivirals, antifungals) within 30 days prior to Baseline or
oral anti-infectives (antibiotics, antivirals, antifungals) within 14 days prior to Baseline, except as required as part of an anti-TB regimen
Subject previously treated with a biologic medication but stopped due to lack of
effect/sufficient effect as deemed by the investigator
Any other active skin disease or condition (e.g., bacterial, fungal or viral infection) that may interfere with assessment of HS
Pregnant (or considering becoming pregnant) or lactating females Note: Non child bearing potential is defined as surgically sterile with a hysterectomy and/or bilateral oophorectomy OR postmenopausal (defined as amenorrhea at least 12 months before screening, confirmed by FSH levels at screening)
Clinically significant abnormal screening laboratory results as evaluated by the Investigator
Subject does not have reliable internet access for weekly electronic surveys
Subject is considered by the Study Investigator, for any reason, to be an unsuitable candidate for the study
Excluded prohibited concomitant medication and procedures include: JAK inhibitors (systemic or topical (eg, ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, and pacritinib) within 4 weeks of Screening ; surgical, laser, or IPL intervention in area with HS lesion within 3 months of Screening, except for rescue lesional treatment; systemic corticosteroid within 4 weeks; use of topical creams, ointments, gels, and liquids except the study therapy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note